About this item:

544 Views | 456 Downloads

Author Notes:

Address for correspondence: John E. McGowan, Jr, Rollins School of Public Health, Emory University, 1518 Clifton Rd (Room 442), Atlanta, GA 30322, USA; email jmcgowa@sph.emory.edu

We thank the microbiology personnel at participating hospitals for sending the isolates included in this study.


Research Funding:

Phase 5 of Project ICARE is supported in part by unrestricted grants to the Rollins School of Public Health of Emory University by Astra-Zeneca Pharmaceuticals, bioMérieux Incorporated, Elan Pharmaceuticals, and Pfizer Incorporated.


  • antimicrobial resistance
  • integron
  • Escherichia coli
  • Klebsiella
  • surveillance

Class 1 Integrons in Resistant Escherichia coli and Klebsiella spp., US Hospitals


Journal Title:

Emerging Infectious Diseases


Volume 12, Number 6


, Pages 1011-1014

Type of Work:

Article | Final Publisher PDF


We examined Escherichia coli and Klebsiella spp. from US hospitals for class 1 integrons. Of 320 isolates, 181 (57%) were positive; association of integrons with resistance varied by drug and organism. Thus, determining integron epidemiology will improve understanding of how antibacterial resistance determinants spread in the United States.

Copyright information:

Emerging Infectious Diseases is published by the Centers for Disease Control and Prevention, a U.S. Government agency. Therefore, all materials published in Emerging Infectious Diseases are in the public domain and can be used without permission.

Export to EndNote